Sandoz launches 'Act4Biosimilars' initiative to help address health inequity and inequality worldwide
1 June 2022 -

Sandoz, a division of Switzerland-based biopharmaceutical company Novartis that is involved in generic and biosimilar medicines, announced on Tuesday the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and inequality worldwide.

Act4Biosimilars aims to increase patient access to advanced medicines by facilitating greater approvability, accessibility, acceptability and affordability (the 4 A's) of biosimilars. The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30-plus countries by 2030.

A biosimilar is a successor to a biological medicine (also known as 'reference medicine') for which the patent has expired and exclusivity has been lost. Biosimilars match their respective reference medicine in terms of quality, safety and efficacy. Hence, the biosimilar can be expected to behave in the same way as the reference medicine in all indications and patient populations that the reference medicines are approved in. Biosimilars are used in the treatment and prevention of many disabling and life-threatening diseases such as cancer, psoriasis, arthritis, and diabetes. outlines the 12 goals that have been identified under the 4As by the Steering Committee to achieve the mission. These include ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development.

'As a result of their affordability, biosimilars have opened up a new realm of possibility for patients by enabling biological medicines to become more widely available to those in need of these advanced, life-changing treatments,' said Zorana Maravic, CEO, Digestive Cancers Europe. 'However, until we address existing biosimilar access inequities, far too many patients will continue to miss out on treatment with the best possible medicines.'